Cochlear sees no other suitors for Demant's implants business
The Australian would-be buyer has serious questions about ”whether any other company has the ability and the willingness” to shoulder the responsibility of Oticon Medical.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
20,000 patients currently using an Oticon Medical implant stand to lose if competition authorities continue to block Demant’s divestment of the surgical unit to Australia-based Cochlear.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
